Spots Global Cancer Trial Database for The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis
Official Title: The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis
Study ID: NCT00794274
Interventions
Study Description
Brief Summary: To determine whether CC-10004, a phosphodiesterase inhibitor, is useful in treating chronic cutaneous sarcoidosis.
Detailed Description: This will be an open label, phase II trial of CC-10004 for chronic cutaneous sarcoidosis. It will include two centers (University of Cincinnati and Medical University of South Carolina). The study will evaluate patients with chronic disease who are on a stable treatment regimen and have no significant change in their Sarcoidosis Skin Activity and Severity Index score (SASI) at two visits at least one month apart.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Cincinnati, Cincinnati, Ohio, United States
Contact Details
Name: Robert P Baughman
Affiliation: University of Cincinnati
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
